Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Location
53 Frontage Road, Suite 220, Hampton, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.1K % +1.99%
Debt-to-equity 5.4 % -4.93%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.4M shares +0.18%
Common Stock, Shares, Outstanding 66.4M shares +0.17%
Entity Public Float 2.4B USD +50%
Common Stock, Value, Issued 66K USD 0%
Weighted Average Number of Shares Outstanding, Basic 66.4K shares +0.57%
Weighted Average Number of Shares Outstanding, Diluted 66.4K shares +0.57%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.79M USD -30.2%
Research and Development Expense 199M USD +46%
General and Administrative Expense 41.5M USD +17.7%
Costs and Expenses 241M USD +30.7%
Operating Income (Loss) -235M USD -33.5%
Net Income (Loss) Attributable to Parent -56.6M USD -57.9%
Earnings Per Share, Basic -3 USD/shares -9.46%
Earnings Per Share, Diluted -3 USD/shares -9.46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23M USD -46.1%
Marketable Securities, Current 607M USD -20%
Assets, Current 648M USD -20.1%
Property, Plant and Equipment, Net 4.39M USD +13.7%
Operating Lease, Right-of-Use Asset 3.12M USD +27.4%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 9.3M USD +8592%
Assets 692M USD -18.1%
Accounts Payable, Current 2.07M USD -45.5%
Employee-related Liabilities, Current 11.6M USD +23.7%
Accrued Liabilities, Current 28.4M USD +52.9%
Liabilities, Current 33M USD +19.2%
Operating Lease, Liability, Noncurrent 1.5M USD +87.8%
Other Liabilities, Noncurrent 2.54M USD -26.8%
Liabilities 37M USD +15.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.34M USD +87.6%
Retained Earnings (Accumulated Deficit) -1.67B USD -13.6%
Stockholders' Equity Attributable to Parent 655M USD -19.5%
Liabilities and Equity 692M USD -18.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.4M USD -33.8%
Net Cash Provided by (Used in) Financing Activities 202K USD -100%
Net Cash Provided by (Used in) Investing Activities 43M USD
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 66.4M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD -114%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23M USD -46.1%
Deferred Tax Assets, Valuation Allowance 320M USD -7.95%
Deferred Tax Assets, Gross 325M USD -7.84%
Operating Lease, Liability 3.81M USD +50%
Payments to Acquire Property, Plant, and Equipment 265K USD -23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -198M USD -31.6%
Lessee, Operating Lease, Liability, to be Paid 4.28M USD +56.4%
Property, Plant and Equipment, Gross 27.8M USD +5.16%
Operating Lease, Liability, Current 1.54M USD -3.34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.78M USD +87.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.76M USD -1.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 469K USD +141%
Lessee, Operating Lease, Liability, to be Paid, Year Three 742K USD
Deferred Tax Assets, Operating Loss Carryforwards 177M USD -10.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 867K USD +11.9%
Share-based Payment Arrangement, Expense 37.9M USD +29.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%